aidsmap.com news feed : Aidsmap news - English

Less resistance with FTC than 3TC when combined with tenofovir

Michael Carter — Mon, 08 Feb 2010 01:00:00 GMT

Amongst patients experiencing a rebound in viral load, those taking 3TC (lamivudine, Epivir) in combination with tenofovir (Viread) were more likely than those taking FTC (emtricitabine, Emtriva) and tenofovir to develop a number of key resistance mutations.

Vision loss affecting one in ten Ugandan people with HIV

Carole Leach-Lemens — Mon, 08 Feb 2010 01:00:00 GMT

The lack of routine eye care was the likely cause of the unrecognised but significant and preventable vision loss and eye disease among 11% of HIV-infected adults attending an HIV treatment site in Kampala, Uganda, report Juliet Otiti-Sengeri and colleagues in the Journal of Acquired Immune Deficiency Syndromes.

Tesamorelin safe and effective for fat accumulation in patients taking HIV treatment

Michael Carter — Wed, 03 Feb 2010 01:00:00 GMT

Treatment with tesamorelin significantly improves visceral fat accumulation in patients with HIV, an international team of investigators report in the online edition of the Journal of Acquired Immune Deficiency Syndromes.

New heat-stable ritonavir tablet approved in Europe

Keith Alcorn — Wed, 03 Feb 2010 01:00:00 GMT

The new heat-stable formulation of ritonavir (Norvir) has been approved in the European Union, manufacturer Abbott announced this week.

Danes find more evidence linking abacavir treatment with increased risk of heart attack

Michael Carter — Tue, 02 Feb 2010 01:00:00 GMT

Researchers have found further evidence suggesting that treatment with abacavir increases the risk of heart attack. In a study published in the February edition of HIV Medicine investigators from Denmark report that patients who took the drug doubled their risk of heart attack.

Adherence: study shows protease inhibitors more forgiving of missed doses, even when treatment out of date

Michael Carter — Tue, 02 Feb 2010 01:00:00 GMT

Less than perfect adherence to HIV treatment regimens significantly increases the risk of resistance developing to drugs in the NNRTI and NRTI classes, investigators report in the January 28^th edition of AIDS.

FDA revises ddI product label to warn of serious liver side-effect

Michael Carter — Mon, 01 Feb 2010 01:00:00 GMT

Medicine regulatory authorities in the US have updated the product information for ddI (didanosine, Videx) to warn that treatment with the drug can cause a serious liver problem.

Second-line ART in South Africa shows good results

Carole Leach-Lemens — Mon, 01 Feb 2010 01:00:00 GMT

High rates of increased CD4 cell counts and viral suppression, together with low mortality were seen in adults at a large HIV public-sector urban clinic in Johannesburg, South Africa after one year on second-line antiretroviral therapy, Matthew P. Fox and colleagues report in a study published online ahead of print in the Journal of Acquired Immune Deficiency Syndromes.

Progestogen-only hormonal contraception linked to metabolic problems in HIV-positive women

Kelly Safreed-Harmon — Fri, 29 Jan 2010 01:00:00 GMT

HIV-positive women using progestogen-only hormonal contraception may be at increased risk for negative metabolic outcomes, warned researchers in a recent article in the Journal of Acquired Immune Deficiency Syndromes.

Genetic marker may predict heart disease risk in people with HIV

Keith Alcorn — Thu, 28 Jan 2010 01:00:00 GMT

A genetic marker associated with atherosclerosis and oxidative stress in mice and humans is strongly associated with the incidence of cardiovascular disease, metabolic syndrome and poorer immune recovery in people with HIV, Spanish researchers report in the February 15th edition of the Journal of Infectious Diseases.